FDA Puts Dose Selection At Top Of Agenda For End-Of-Phase 2A Meetings
Executive Summary
Drug sponsors should use end-of-Phase 2A meetings for the in-depth discussions with FDA regarding dose estimation and selection that other pre-submission meetings do not allow for, according to a 1draft guidance